Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
387 studies found for:    biogen | biogen
Show Display Options
Rank Status Study
21 Completed Study of Oral CNF2024 (BIIB021) in Advanced Solid Tumors
Conditions: Tumors;   Lymphoma
Intervention: Drug: CNF2024
22 Completed Is IFN-beta Treatment in MS Useful After a Washout Period in Patients With Neutralizing Antibodies to Interferon Beta
Condition: Relapsing-Remitting Multiple Sclerosis
Interventions: Drug: Interferon-beta-1a;   Drug: methylprednisolone
23 Completed Simvastatin as an Add-on Treatment to Interferon-beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis
Condition: Multiple Sclerosis
Interventions: Drug: Interferon-beta-1a;   Drug: Simvastatin;   Drug: Placebo
24 Terminated Evaluation of Safety and Efficacy of Fludarabine, Cyclophosphamide, and Rituximab (FCR) +/- Lumiliximab in Subjects With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: Lumiliximab + FCR;   Drug: FCR
25 Completed Assessment Of The Safety And Efficacy Of BG9924 In Rheumatoid Arthritis (RA) Participants
Condition: Rheumatoid Arthritis
Interventions: Biological: Baminercept alfa 1;   Biological: Placebo;   Biological: Baminercept alfa 2;   Biological: Baminercept alfa 3;   Biological: Baminercept alfa 4;   Biological: Baminercept alfa 5
26 Completed Pharmacokinetics Profile Study of BG00012 Standard Formulation and BG00012 Active Pharmaceutical Ingredient
Condition: Healthy
Intervention: Drug: BG00012
27 Completed A Multicenter Study to Assess the Effect of Plasma Exchange in Accelerating the Clearance of Natalizumab in Subjects With Multiple Sclerosis (MS)
Condition: Relapsing Forms of Multiple Sclerosis
Interventions: Procedure: Plasma exchange;   Drug: natalizumab treatment
28 Completed A Single-blinded, Controlled, Multi-centre Study of Effects of Exercise in Participants With Multiple Sclerosis
Condition: Exercise
29 Completed Study of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Subjects With Severe Hemophilia A
Condition: Severe Hemophilia A
Intervention: Drug: rFVIIIFc
30 Completed
Has Results
A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (Tysabri®) Improves Ambulatory Measures in Relapsing-remitting Multiple Sclerosis (RRMS) Patients
Condition: Relapsing Remitting Multiple Sclerosis (RRMS)
Intervention: Drug: BG00002 (natalizumab)
31 Completed Using PET Scans to Study Brain Receptor Occupancy of BIIB014 in Healthy Male Volunteers
Condition: Healthy
Interventions: Drug: BIIB014;   Other: [11C]SCH442416
32 Completed Dose-Finding Safety Study of BIIB014 in Combination With Levodopa in Moderate to Late Stage Parkinson's Disease
Condition: Parkinson's Disease
Interventions: Drug: BIIB014;   Drug: Placebo
33 Completed Dose-Finding Safety Study of BIIB014 in Early-Stage Parkinson's Disease
Condition: Parkinson's Disease
Interventions: Drug: BIIB014;   Drug: Placebo
34 Recruiting A Study of Multiple Doses of Nusinersen (ISIS 396443) Delivered to Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy
Condition: Spinal Muscular Atrophy
Intervention: Drug: Nusinersen
35 Not yet recruiting Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natalizumab
Condition: Relapsing-Remitting Multiple Sclerosis (RRMS)
Intervention: Drug: Daclizumab
36 Recruiting Study to Evaluate BIIB059 in CLE With or Without SLE
Conditions: Systemic Lupus Erythematosus (SLE);   Active Cutaneous Lupus Erythematosus (CLE)
Interventions: Drug: BIIB059;   Drug: Placebo
37 Recruiting PK and Safety Study of BIIB074 in Healthy Japanese and Caucasian Participants
Condition: Trigeminal Neuralgia
Interventions: Drug: BIIB074;   Drug: Placebo
38 Recruiting A Phase 1, Single-Ascending-Dose, Safety, Tolerability, Pharmacokinetic(PK), and Pharmacodynamic(PD) Study of BIIB068 in Healthy Participants
Condition: Systemic Lupos Erythematosus, SLE
Interventions: Drug: BIIB068;   Drug: Placebo
39 Recruiting Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)
Condition: Multiple Sclerosis
40 Recruiting Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke
Condition: Acute Ischemic Stroke
Interventions: Drug: natalizumab;   Drug: Placebo

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years